QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors
To assess the safety, tolerability, and pharmacokinetic profiles of AMG 479 when used in combination with bevacizumab, sorafenib, panitumumab, erlotinib, or gemcitabine in subjects with advanced solid tumors. Up to 126 subjects may be enrolled. Sorafenib and erlotinib combo cohorts are enrolling. All other combo cohorts are closed to enrollment.
Advanced Malignancy|Advanced Solid Tumors|Cancer|Solid Tumors|Tumors
DRUG: AMG 479
To assess the safety, tolerability, and pharmacokinetic profiles of AMG 479 when used in combination with bevacizumab, sorafenib, panitumumab, erlotinib or gemcitabine in subjects with advanced solid tumors, 3 years
To evaluate pharmacokinetic (PK) profiles of biologics or chemotherapy when used in combination with AMG 479, 3 years|To evaluate tumor response as assessed by World Health Organization (WHO) criteria, 3 years|To evaluate tumor response as measured by volumetric computed tomography (CT), 3 years|To evaluate anti-AMG 479 antibody response following AMG 479 administration, 3 years
To assess the safety, tolerability, and pharmacokinetic profiles of AMG 479 when used in combination with bevacizumab, sorafenib, panitumumab, erlotinib, or gemcitabine in subjects with advanced solid tumors. Up to 126 subjects may be enrolled. Sorafenib and erlotinib combo cohorts are enrolling. All other combo cohorts are closed to enrollment.